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A B S T R A C T
Background
Polycystic ovarian syndrome (PCOS) is one of the most common reproductive endocrinology abnormalities, and affects 5% to 10%
of women of reproductive age. Western medicines, such as oral contraceptives, insulin sensitizers and laparoscopic ovarian drilling
(LOD), have been used to treat PCOS. Recently, many studies have been published that consider Chinese herbal medicine (CHM) as
an alternative treatment for women with PCOS.
Objectives
To assess the efficacy and safety of CHM for subfertile women with PCOS.
Search methods
We searched sources, including the following databases, from inception to 9 June 2016: the Cochrane Gynaecology and Fertility
Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Allied and
Complementary Medicine (AMED), PsycINFO, Chinese National Knowledge Infrastructure (CNKI), VIP, Wanfang and trial registries.
In addition, we searched the reference lists of included trials and contacted experts in the field to locate trials.
Selection criteria
Randomized controlled trials (RCTs) that considered the use of CHM for the treatment of subfertile women with PCOS.
Data collection and analysis
Two review authors independently screened appropriate trials for inclusion, assessed the risk of bias in included studies and extracted data.
We contacted primary study authors for additional information. We conducted meta-analyses. We used the odds ratios (ORs) to report
dichotomous data, with 95% confidence intervals (CI). We assessed the quality of the evidence using the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) methods.
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Main results
We included five RCTs with 414 participants. The comparisons in the included trials were as follows: CHM versus clomiphene, CHM
plus clomiphene versus clomiphene (with or without ethinyloestradiol cyproterone acetate (CEA)), CHM plus follicle aspiration plus
ovulation induction versus follicle aspiration plus ovulation induction alone, and CHM plus laparoscopic ovarian drilling (LOD) versus
LOD alone. The overall quality of the evidence for most comparisons was very low.
None of the included studies reported live birth rate, and only one study reported data on adverse events.
When CHM was compared with clomiphene (with or without LOD in both arms), there was no evidence of a difference between the
groups in pregnancy rates (odds ratio (OR) 1.98, 95% confidence interval (CI) 0.78 to 5.06; two studies, 90 participants, I² statistic =
0%, very low quality evidence). No study reported data on adverse events. When CHM plus clomiphene was compared with clomiphene
(with or without CEA), there was low quality evidence of a higher pregnancy rate in the CHM plus clomiphene group (OR 2.62, 95%
CI 1.65 to 4.14; three RCTs, 300 women, I² statistic = 0%,low quality evidence). No data were reported on adverse events.
When CHM with follicle aspiration and ovulation induction was compared with follicle aspiration and ovulation induction alone,
there was no evidence of a difference between the groups in pregnancy rates (OR 1.60, 95% CI 0.46 to 5.52; one study, 44 women, very
low quality evidence), severe luteinized unruptured follicle syndrome (LUFS) (OR 0.60, 95% CI 0.06 to 6.14; one study, 44 women,
very low quality evidence), ovarian hyperstimulation syndrome (OHSS) (OR 0.16, 95% CI 0.00 to 8.19; one study, 44 women, very
low quality evidence) or multiple pregnancy (OR 0.60, 95% CI 0.06 to 6.14; one study, 44 women, very low quality evidence).
When CHM with LOD was compared with LOD alone, there was no evidence of a difference between the groups in rates of pregnancy
(OR 3.50, 95% CI 0.72 to 17.09; one study, 30 women, very low quality evidence), No data were reported on adverse events.
There was no evidence of a difference between any of the comparison groups for any other outcomes. The quality of the evidence for all
other comparisons and outcomes was very low. The main limitations in the evidence were failure to report live birth or adverse events,
failure to describe study methods in adequate detail and imprecision due to very low event rates and wide CIs.
Authors’ conclusions
There is insufficient evidence to support the use of CHM for women with PCOS and subfertility. No data are available on live birth,
and there is no consistent evidence to indicate that CHM influences fertility outcomes. However there is very limited low quality
evidence to suggest that the addition of CHM to clomiphene may improve pregnancy rates. There is insufficient evidence on adverse
effects to indicate whether CHM is safe.
P L A I N L A N G U A G E S U M M A R Y
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Review question
We reviewed the evidence about the effect of Chinese herbal medicines (CHM) on rates of live birth pregnancy and adverse events in
subfertile women with polycystic ovarian syndrome (PCOS).
Background
PCOS is a common and complex reproductive endocrine disorder, affecting 5% to 10% of women of reproductive age. Women with
PCOS may present with irregular menstrual cycles, subfertility (failure to conceive), hirsutism (excessive hair growth), acne and obesity.
Many western medical therapies have been used to manage PCOS, such as oral contraceptives, insulin sensitizers and laparoscopic
ovarian drilling (LOD). CHM have been suggested as an alternative approach for subfertile women with PCOS. We wanted to
investigate the effectiveness and safety of CHM compared to other therapies for subfertile women with PCOS.
Study characteristics
We searched evidence from commonly used databases and it is current to 9 June 2016. We included five RCTs with 414 participants.
These included studies comparing CHM to western medicine, CHM plus western medicine versus western medicine, and CHM plus
surgery versus surgery. All the included studies were in Chinese. All studies had fewer than six menstrual cycles treatment duration and
less than one year follow-up duration. None of the included studies reported live birth, all reported pregnancy, two reported ovulation
and only one reported adverse events.
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Key results
There was insufficient evidence to support the use of CHM for women with PCOS and subfertility. No data were available on live birth,
and there was no consistent evidence to indicate that CHM improves fertility outcomes. When CHM was compared with clomiphene
(with or without laparoscopic ovarian drilling (LOD) in both arms), the pregnancy rates were no different between the groups. When
CHM with follicle aspiration and ovulation induction was compared with follicle aspiration and ovulation induction alone, pregnancy
rates were no different between the groups. When CHM with LOD was compared with LOD alone, the pregnancy rates were no
different between the groups. However there was limited low quality evidence to suggest that the addition of CHM to clomiphene may
improve pregnancy rates. There was no evidence of a difference between any of the comparison groups for any other outcomes. There
was insufficient evidence on adverse effects to indicate whether CHM is safe.
Quality of the evidence
The quality of the evidence was low or very low. The main limitations in the evidence were failure to report live birth or adverse events,
failure to describe study methods in adequate detail, and imprecision, with very low event rates and wide confidence intervals.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CHM versus clomiphene for subfertile women with PCOS
Population: subfert ile women with PCOS
Setting: f ert il ity clinics
Intervention: Chinese herbal medicine (CHM)
Comparison: clomiphene




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Clomiphene CHM
Live birth rate Not reported








Adverse ef fects Not reported
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relat ive ef fect of the intervent ion (and its 95% CI)
Abbreviat ions: CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Downgraded one level for serious risk of bias: study methods not described in suf f icient detail.
2Downgraded two levels for very serious imprecision: small sample size, only 32 events altogether, CIs compatible with no











































































































B A C K G R O U N D
Description of the condition
Polycystic ovarian syndrome (PCOS) is a complex condition that
affects 5% to 10% of women of reproductive age (Carmina 1999).
PCOS is characterized by chronic anovulation (ongoing failure
or absence of ovulation), hyperandrogenism (excessive production
of androgen in women), dyslipidaemia (lipid metabolism disor-
der), and insulin resistance (a reduced glucose response to a given
amount of insulin) leading to hyperinsulinaemia (compensatory
serum insulin increase). Women with PCOS may present with
irregular menstrual cycles, subfertility (failure to conceive), hir-
sutism (excessive hair growth), acne and obesity. The cause of
PCOS remains unclear. It is proposed that high levels of andro-
gen in serum may be the primary cause (Escobar-Morreale 2005).
However, insulin resistance and obesity may also trigger the de-
velopment of this hormonal defect (Dunaif 1997; Alvarez-Blasco
2006; Gambineri 2006). Other conditions associated with PCOS
include type 2 diabetes mellitus (Ehrmann 1999; Legro 1999), ges-
tational diabetes (Boomsma 2006; Lo 2006a), decreased high den-
sity lipoprotein cholesterol (HDL-C) (Rajkhowa 1997; Berneis
2007), increased triglycerides (TG) and low density lipoprotein
cholesterol (LDL-C) (Talbott 1998; Legro 2001), increased risk
of hypertension (high blood pressure) (Lo 2006b), and increased
prevalence of metabolic syndrome.
Traditional Chinese Medicine (TCM) follows an independent the-
oretical and methodological pathway to assess the cause of the dis-
ease for making the diagnosis and treatment plan. Even though
there is no classification for PCOS within TCM, the symptoms
and signs of women with PCOS can be grouped as two disease
classes within TCM: amenorrhoea (failure to menstruate) and in-
fertility.
Studies of PCOS and TCM have been conducted since the 1980s
(Sun 1981; Yv 1981; Wang 1982). The aetiology and clinical
characteristics of PCOS still remain controversial but are believed
to be related to the disorders of kidneys, liver and spleen, and
from the TCM perspective reproductive function is regarded as
being governed by kidneys. It is believed that kidney deficiency
may be the main problem in PCOS (Ni 2007; Wang 2008). In
addition, in TCM there is an association between the liver and
the regulation of blood and the menstrual cycle, and the spleen is
associated with body type, obesity and hirsutism (Liu 2009; Hou
2012).
Description of the intervention
Many Western medicine therapies have been used for PCOS, in-
cluding oral contraceptives, insulin sensitizers, exercise, diet and
laparoscopic ovarian drilling (LOD). Several Cochrane reviews
have addressed different approaches to PCOS using Western med-
ical treatments (Weiss 2015; Tang 2012; Costello 2007; Farquhar
2012; Sinawat 2012). The oral contraceptive pill (OCP) is believed
to be more effective than insulin-sensitizing drugs in improving
menstrual patterns and reducing serum androgen levels (Costello
2007). On the other hand, metformin, an insulin-sensitizing drug
(ISD), has been found to be more effective than the OCP in re-
ducing fasting insulin levels and not increasing triglyceride levels
(Costello 2007). Metformin, either alone or in combination with
clomiphene, increases ovulation in women with PCOS and may
reduce health risks from insulin resistance and the effect of ab-
normal levels of androgen. However, the possible adverse effects
from using metformin could include nausea and vomiting (Tang
2012). The optimal duration for metformin pretreatment before
initiation of clomiphene citrate is unknown (Sinawat 2012). Go-
nadotrophin is used for ovulation induction but it may also cause
overstimulation of the ovaries. A reduced incidence of overstim-
ulation was found with the use of more expensive urinary follicle
stimulating hormone (uFSH) compared to human menopausal
gonadotrophin (HMG). A higher overstimulation rate with the
addition of gonadotrophin releasing hormone analogues (GnRH-
a) to gonadotrophins is suggested (Weiss 2015). LOD followed
by clomiphene or gonadotrophins, if necessary, are suggested to
be as effective as gonadotrophin therapy alone in inducing ovu-
lation. However, LOD is associated with a lower risk of multiple
pregnancy (Farquhar 2012).
Chinese herbal medicines (CHM) are used broadly in various en-
docrinologic disorders. CHM is used with the aim of improving
menstrual patterns, hirsutism, acne and pregnancy rate in women
with PCOS (Cong 2006; Yang 2006; Ma 2010). In TCM, there
are three different therapeutic strategies to treat PCOS by CHM.
Firstly, only one special formula comprising of sovereign medici-
nal (the ingredient that provides the principal curative action on
the main pattern/syndrome or primary symptom) is prescribed
to women for the whole menstrual cycle. This formula is occa-
sionally combined with some minister medicinal (the ingredient
that helps strengthen the principal curative action) and assistant
medicinal (the ingredient that treats the combined pattern/syn-
drome, relieves secondary symptoms or tempers the action of the
sovereign ingredient when the latter is too potent) accordingly
to one’s individual symptoms and signs (Cui 2004; Ning 2004;
Xia 2004; Zhang 2004; Liu 2005; Wang 2005; Cong 2006; Yang
2006). Secondly, different formulae are periodically prescribed to
women with PCOS according to each individual’s menstrual cycle.
This strategy is aimed to restore normal reproductive endocrino-
logical function (Yuan 2003; Xue 2004). Thirdly, Chinese herbal
medicines are used in combination with Western medicines for
treating PCOS (Li 2000; Li 2002; Ye 2004; Lin 2005; Li 2006).
How the intervention might work
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Holistic therapy and multisystem regulation are the therapeutic
characteristics of TCM. Many CHM used in treating PCOS are
aimed to tone the kidneys to induce ovulation. The components
of different formulae act synergistically in various ways. For ex-
ample, it is proposed that Baishao (Radix paeoniae alba), Danggui
(Radix angelicae sinensis) and Zaojiao (Fructus gleditsiae sinensis)
reduce release of insulin and androgen (Li 2005), and that Lu-
ole (Basil) has an oestrogenic effect which prompts follicles to de-
velop and mature (Jin 1986). In addition, it is reported that Di-
long (Lumbricus), Sanqi (Radix notoginseng), Zelan (Herba lycopi)
and Zexie (Rhizoma alismatis) can induce ovulation (Shao 2006),
and that Gancao (Radix glycytthizae) which possesses glucocor-
ticoid effects, can improve ovulatory abnormality. It is reported
that Zishiyin (Fluoritum) can improve endometrial receptivity for
embryo implantation and can regulate cervical mucus for sperm
passing through the uterus (Wang 2008).
Why it is important to do this review
Various Western medicine therapies have been used for PCOS in
recent decades. Their effectiveness varies and some are associated
with adverse events. CHM has been used for thousands of years
to treat PCOS, which has a different name in TCM. In both de-
veloped and developing countries, there is increasing public inter-
est in, and use of, a wide range of therapies which lie outside the
’mainstream’ of traditional Western medical practice. Although
CHM is generally considered safe when used properly by qual-
ified practitioners, many herbs and formulae have contraindica-
tions, and some can be toxic. There are concerns about adverse
events, including allergic reactions and Chinese herbal nephropa-
thy (CHN) (Nortier 2000; Lord 2001; Lampert 2002).
As there is currently insufficient evidence about the safety and ef-
ficacy of CHM for the management of PCOS, a systematic review
in this area was warranted. No systematic review on this topic has
been done before. This is an update of a review first published in
2010 (Zhang 2010)
O B J E C T I V E S
To assess the efficacy and safety of Chinese herbal medicine
(CHM) for subfertile women with polycystic ovarian syndrome
(PCOS).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) studying the efficacy of Chi-
nese herbal medicine (CHM) for subfertile women with polycys-
tic ovarian syndrome (PCOS).
We excluded quasi-RCTs and non-RCTs.
Types of participants
Women with PCOS and subfertility wishing to conceive (18 to 44
years). We excluded trials that included both fertile and infertile
women with PCOS unless there was a stratified analysis based on
fertility.
We defined PCOS using the diagnostic criteria of the European
Society of Human Reproduction and Embryology (ESHRE) and
the American Society of Reproductive Medicine (ASRM) consen-
sus in Rotterdam 2003 (ESHRE/ASRM 2004). PCOS can be di-
agnosed if a woman has two out of three criteria: oligo or anovula-
tion, clinical or biochemical signs of hyperandrogenism and poly-
cystic ovaries by ultrasonography. These diagnostic criteria exclude
individuals who have other aetiologies of hyperandrogenism (such
as androgen secreting tumour, hyperprolactinaemia, dysthyroid
disease, Cushing syndrome and congenital adrenal cortical hyper-
plasia).
Ideally, the trials that we considered for inclusion in this review
stated and described the diagnostic criteria of PCOS. If the pri-
mary study did not employ the Rotterdam criteria, we evaluated
the stated diagnostic criteria in each individual study to confirm
whether they met the Rotterdam criteria.
We excluded trials whose diagnostic criteria were inconsistent with
Rotterdam criteria. If the trial did not clearly state the diagnos-
tic criteria, we contacted the primary study authors for clarifica-
tion. If clarification was unavailable, we also excluded these tri-
als. Changes in diagnostic criteria might produce variability in the
clinical characteristics of the women included and the results ob-
tained. We considered and documented these changes. We plan
to perform sensitivity analyses based on these changes when we
locate more RCTs that meet the inclusion criteria of this review in
the future.
Types of interventions
1. CHM versus: placebo, no treatment, Western medicine,
exercise plus diet control, laparoscopic surgery, another type of
CHM, with or without co-medications.
2. CHM combined with another treatment versus another
treatment, such as Western medicine, exercise plus diet control
or laparoscopic surgery.
3. CHM alone or combined with another treatment versus
CHM combined with another treatment.
We excluded trials that included ovarian wedge resection as the
control intervention because physicians have not used this method
since the application of laparoscopic ovarian drilling (LOD).
We excluded trials without CHM application.
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Types of outcome measures
Primary outcomes
1. Live birth rate (per woman).
Secondary outcomes
1. Pregnancy rate per woman.
2. Ovulation rate (confirmed by ultrasound or increased
progesterone) per woman.
3. Adverse events (severe or minor).
We defined serious adverse events according to the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) Guide-
lines (ICHEWG 1997) and they included any event that led to
death, was life-threatening, required inpatient hospitalization or
prolongation of existing hospitalization, or resulted in persistent or
significant disability, and any important medical event that might
have jeopardized the patient or required intervention to prevent
it. For example, we considered severe ovarian hyperstimulation
syndrome (OHSS) and severe luteinized unruptured follicle syn-
drome (LUFS) that required in-patient hospitalization as serious
adverse events in this review. We considered all other adverse events
as non-serious.
We excluded trials that did not measure any of above outcomes.
Search methods for identification of studies
In consultation with the Cochrane Gynaecology and Fertility
Group (CGF) Information Specialist, we formulated a compre-
hensive search strategy in order to identify all RCTs regardless of
language or publication status (published, unpublished, in press
or in progress).
Electronic searches
In this review update, we searched the following databases up to
9 June 2016.
1. The CGF Specialized Register.




5. Allied and Complementary Medicine (AMED).
6. PsycINFO.
7. Chinese National Knowledge Infrastructure (CNKI,
including Chinese journal full-text database (CJFD), Chinese
selected doctoral dissertations and Master’s theses full-text
databases (CDMD)).
8. Chinese important conference dissertations full-text
database (from 2000 to June 2016), VIP (from 1989 to June
2016).
9. Wanfang database (from 1998 to June 2016).
We constructed search strategies using a combination of subject
headings and text words relating to the use of traditional Chinese
herbal medicines for the management of PCOS (Appendix 1; Ap-
pendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6; Ap-
pendix 7; Appendix 8; Appendix 9; Appendix 10). We translated
all of the search terms into Chinese terms when we conducted the
searches in Chinese databases.
We combined the MEDLINE search with the Cochrane highly
sensitive search strategy for identifying randomized trials which
appears in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Version 5.0.2 chapter 6, 6.4.11) (Higgins 2011).
We combined the EMBASE search with trial filters developed by
the Scottish Intercollegiate Guidelines Network (SIGN) (http://
sign.ac.uk/mehodology/filters.html#random).
We searched the following for ongoing trials (9 June 2016).
1. The ISRCTN Register (international); Action Medical
Research (UK); NIHR Health Technology Assessment
Programme (HTA) (UK); The Wellcome Trust (UK); Medical
Research Council (UK); UK trials (UK); NIH Clinical Trials.gov
Register (International) (http://www.controlled-trials.com/
mrct/).
2. The World Health Organization International Trials
Registry Platform search portal (http://apps.who.int/trialsearch/
Default.aspx).
3. The Chinese Clinical Trial Registry (http://www.chictr.org/
Site/Search.aspx?lang=CN).
Searching other resources
We checked the reference lists of relevant trials, reviews and text-
books. We contacted experts in the field and pharmaceutical com-
panies for relevant trials.
Data collection and analysis
Selection of studies
Two review authors independently performed the searches and
retrieved articles (ZK, ZJ). We retrieved the searched trials that
claimed to be randomized; two review authors (ZK, ZJ) then con-
firmed that these trials were correctly randomized by telephon-
ing the original trial authors to evaluate the methodological qual-
ity. We judged trials to be adequately randomized if they met the
set criteria (Schulz 1995; Jadad 1996; Moher 1998; Jüni 2001;
Kjaergard 2001). Two review authors (ZK, ZJ) selected the trials
to be included in the review and resolved any disagreements by
discussion with a third review author (WT). Also, we listed the ex-
cluded studies and the reasons for exclusion in the ’Characteristics
of excluded studies’ table. See Figure 1 for details of the screening
and selection process.
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Figure 1. Study flow diagram.
Data extraction and management
Two review authors (ZK, XL) independently extracted data us-
ing a piloted data extraction form. We extracted data on study
characteristics including methods, participants, interventions and
outcomes (see the ’Characteristics of included studies’ table). We
resolved any disagreements by discussion. We have listed the for-
mulation contents of the included studies and herb names in three
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languages in Table 1 and Table 2.
Assessment of risk of bias in included studies
Two review authors (ZJ, XL) independently performed the ’Risk
of bias’ assessments using the Cochrane ’Risk of bias’ tool, Higgins
2011, to assess the following domains.
1. Sequence generation: randomized (for example, by
computer, random number tables or drawing lots) or method of
randomization not described (we excluded quasi-RCTs).
2. Allocation concealment: low risk of bias (for example, by
third party, sealed opaque envelopes); high risk of bias (for
example, open list of allocation codes); unclear risk of bias (for
example, not stated, or ’envelopes’ stated without further
description).
3. Blinding of participants, personnel and outcome assessors.
4. Completeness of outcome data.
5. Selective outcome reporting.
6. Other sources of bias.
Measures of treatment effect
We only measured dichotomous data in this review. We compared
the outcome measures for binary data by calculating Peto-odds
ratios (Peto OR) with 95% confidence intervals (CI). To measure
the treatment effect we conducted intention to treat (ITT) analy-
ses.
Unit of analysis issues
We planned that we would assess any studies with non-standard
designs, such as cluster-RCTs, to avoid unit-of-analysis errors in-
cluding: recruitment bias, baseline imbalance, loss of clusters, in-
correct analysis and comparability with individually RCTs.
Dealing with missing data
We attempted to contact the trial authors to ask for missing data,
but were unsuccessful. We imputed outcomes where data were
missing in the present review. We assumed failure for drop-outs
in the treatment group and success for drop-outs in the control
group.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a clinically meaningful summary. We assessed
statistical heterogeneity by using the Chi² test with a 10% level of
statistical significance and by the I² statistic to estimate the total
variation across studies that is due to heterogeneity rather than
chance. We considered less than 25% to indicate low level hetero-
geneity; 25% to 50% as a moderate level; and greater than 50% to
indicate substantial heterogeneity (Higgins 2002; Higgins 2011).
Assessment of reporting biases
In view of the difficulty of detection of and correction for publica-
tion bias and other reporting biases, we planned to minimize their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert for duplication of data. If there were 10
or more studies in an analysis, we planned to use a funnel plot to
explore the possibility of small study effects (a tendency for esti-
mates of the intervention effect to be more beneficial in smaller
studies).
Data synthesis
We planned that two review authors (ZK, ZJ) would pool data if
studies were sufficiently similar, using Review Manager (RevMan)
(RevMan 2014). If pooling was inappropriate, we planned to per-
form only descriptive analysis. We planned to use a fixed-effect
model unless there was substantial heterogeneity, in which case we
would use a random-effects model.
We planned to combine the data from primary studies in the
following comparisons:
1. CHM versus clomiphene.
2. CHM + clomiphene versus clomiphene.
3. CHM + follicle aspiration + ovulation induction versus
follicle aspiration + ovulation induction.
4. CHM + LOD versus LOD.
Subgroup analysis and investigation of heterogeneity
Where data were available, we planned to conduct subgroup anal-
yses to determine the separate evidence within the following sub-
groups.
1. Different co-interventions.
2. Different treatment strategies.
3. The duration of intervention or follow-up.
4. Women with or without insulin resistance.
5. Women with or without obesity.
6. Ethnicity.
If we detected substantial heterogeneity, we planned to explore
possible explanations in sensitivity analyses and to take any statis-
tical heterogeneity into account when we interpreted the results,
especially if there was any variation in the direction of effect.
Sensitivity analysis
We planned to conduct sensitivity analyses for the primary out-
comes to determine whether the conclusions were robust to arbi-
trary decisions made regarding eligibility and analysis. These anal-
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yses would include consideration of whether the review conclu-
sions would have differed under the following circumstances.
1. We restricted eligibility to studies without high risk of bias.
2. We adopted a random-effects model
3. We restricted eligibility to studies without commercial
funding.
R E S U L T S
Description of studies
We have reported the characteristics of the included and excluded
studies in the ’Characteristics of included studies’ table and the
’Characteristics of excluded studies’ table.
Results of the search
The search from inception to June 2016 retrieved 899 articles
(excluding duplications): 163 in English and 736 in Chinese. Of
these 899 articles, 146 were animal or experimental studies, 55
were non-polycystic ovarian syndrome (PCOS) studies, 69 were
non-Chinese herbal medicine (CHM) studies, 92 included par-
ticipants who were adolescent or had PCOS without infertility or
had no wish to conceive, 19 were before-and-after studies, 18 were
reviews, nine were case-control studies, nine were case reports, two
were cross-sectional studies, three were parallel non-randomized
controlled studies, 27 were systematic reviews , 17 were unrelated
studies and 3 were duplications. Finally, 430 articles were poten-
tially eligible and we retrieved the full-text of these articles. Seven
studies met our inclusion criteria (Li 2007; Ye 2007; Liang 2008;
Ma 2009a; Li 2012a; NCT01116167; ChiCTR-IOR-16008557);
one was a new study to this review (Li 2012a), and two were ongo-
ing studies (NCT01116167; ChiCTR-IOR-16008557). Finally,
we included five studies in this review (Li 2007; Ye 2007; Liang
2008; Ma 2009a; Li 2012a), and excluded 426 articles. See the
’Characteristics of included studies’ table and the ’Characteristics
of excluded studies’ table for further details.
We prepared a PRISMA flow diagram to describe the articles found
from our searches (Figure 1).
Included studies
Study design
All five included studies were conducted and published in China.
One was a double clinical centre design (Liang 2008), and the
other four were single-centre studies. Three studies used two-arm
parallel groups (Liang 2008; Ma 2009a; Li 2012a), and the other
two studies used three-arm parallel groups (Li 2007; Ye 2007).
The range of study duration was from one year to four years.
Each included study reported the inclusion and exclusion criteria.
Drop-outs and withdrawals occurred in three studies for different
reasons (Li 2007; Liang 2008; Ma 2009a).
Participants
In this review update, the five studies included a total of 414 par-
ticipants. Sample size ranged from 40 to 170. All participants were
women of reproductive age, with PCOS (according to Rotterdam
criteria) and subfertility. Furthermore, two included studies also
had the inclusion criterion that participants were resistant to West-
ern medicines for ovulation induction (Ye 2007; Liang 2008). The
baseline characteristics among groups were comparable for each
study.
Interventions
Two studies used Chinese patent drugs (Li 2007; Li 2012a), and
the other three included studies used Chinese herbal formulas. We
have listed the contents of each CHM preparation in Table 1, and
the names of each herbal medicinal in three languages in Table 2.
The treatment duration was less than six menstrual cycles for all
included studies. However, the duration of follow-up was three
months (Liang 2008), one year (Ye 2007), and unclear (Li 2007;
Ma 2009a; Li 2012a), respectively.
1. CHM versus clomiphene:
i) one study compared CHM versus clomiphene (Li
2007);
ii) one study compared CHM plus laparoscopic ovarian
drilling (LOD) and clomiphene plus LOD (Ye 2007).
2. CHM + clomiphene versus clomiphene:
i) two studies compared CHM + clomiphene versus
clomiphene (Li 2007; Li 2012a);
ii) one study compared CHM + ethinyloestradiol
cyproterone acetate (CEA) + clomiphene versus CEA +
clomiphene (Ma 2009a).
3. CHM + follicle aspiration + ovulation induction versus
follicle aspiration + ovulation induction:
i) one study compared CHM+follicle
aspiration+ovulation induction versus follicle
aspiration+ovulation induction (Liang 2008).
4. CHM + LOD versus LOD:
i) one study compared CHM + LOD versus LOD (Ye
2007).
Outcomes
1. No study reported live birth rate.
2. All five included studies reported clinical pregnancy rate (Li
2007; Ye 2007; Liang 2008; Ma 2009a; Li 2012a).
3. One study reported ovulation rate (Ye 2007).
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4. One study reported adverse events (luteinized unruptured
follicle syndrome (LUFS), ovarian hyperstimulation syndrome
(OHSS) and multiple pregnancy) (Liang 2008).
Excluded studies
We excluded 424 studies from the review for the following rea-
sons (see the ’Characteristics of excluded studies’ table for further
details).
1. 122/424 were not RCTs.
2. 178/424 had participants that were not of interest to this
review.
3. 50/424 reported interventions that were not of interest to
this review.
4. 71/424 reported outcomes that were not of interest to this
review.
5. 3/424 were duplicates of already excluded studies.
Risk of bias in included studies
We have summarized the risks of bias of the included studies in
Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgments about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgments about each ’Risk of bias’ item for each included
study.
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Allocation
Four studies were at low risk of selection bias related to sequence
generation as they used random numbers tables (Ye 2007; Liang
2008; Ma 2009a; Li 2012a). One study did not describe the
method used and was at unclear risk of this bias (Li 2007).
One study was at high risk of selection bias related to allocation
concealment as the random number table was open (Liang 2008).
Four studies were at unclear risk of selection bias as they did not
report adequate details to establish whether an appropriate method
of allocation concealment had been used (Li 2007; Ye 2007; Ma
2009a; Li 2012a).
Blinding
1. One study used placebo drugs and described blinding of
participants and outcome assessors. We judged it to be at low
risk of detection bias (Li 2007).
2. One study used no blinding, which the study authors
confirmed. We judged it to be at high risk of bias (Liang 2008).
3. Three studies did not mention blinding. We judged them
to be at unclear risk of bias (Ye 2007; Ma 2009a; Li 2012a).
Incomplete outcome data
Two studies analysed all or most (over 95%) women random-
ized and we judged them to be at low risk of bias (Li 2007; Ma
2009a). One study analysed only 91% of women randomized and
we judged it to be at unclear risk of bias (Liang 2008). Two studies
did not mention drop-outs or withdrawals, and we judged them
as at unclear risk of attrition bias (Ye 2007; Li 2012a). The reasons
for attrition included moving to another place, pelvic inflamma-
tion and conversion to in vitro fertilization-embryo transfer (IVF-
ET).
Selective reporting
The risk of selective reporting was unclear in each of the included
studies, as the protocols of the included studies were unavailable.
The five studies did not assess live birth rate. Only one study re-
ported adverse events (Liang 2008). We were unable to obtain de-
tailed information from the primary study authors. The outcomes
of these five included studies might be influenced by the bias of
selective reporting or publication bias, and we rated all as at un-
clear risk of selective reporting bias.
Other potential sources of bias
We did not identify any other potential sources of bias in the
included studies, and judged each of the included studies at low
risk of other potential sources of bias.
Publication bias
As there were fewer than 10 included studies, we did not assess
potential publication bias using a funnel plot or other corrective
analytical methods (Egger 1997).
Effects of interventions
See: Summary of findings for the main comparison Chinese
herbal medicine (CHM) versus clomiphene for subfertile
women with polycystic ovarian syndrome (PCOS); Summary
of findings 2 Chinese herbal medicine (CHM) + clomiphene
versus clomiphene for subfertile women with polycystic ovarian
syndrome (PCOS); Summary of findings 3 Chinese herbal
medicine (CHM) + follicle aspiration + ovulation induction versus
follicle aspiration + ovulation induction for subfertile women with
polycystic ovarian syndrome (PCOS); Summary of findings 4
Chinese herbal medicine (CHM) + laparoscopic ovarian drilling
(LOD) versus LOD for subfertile women with polycystic ovarian
syndrome (PCOS)
We extracted summary data from the five included studies (Li
2007; Ye 2007; Liang 2008; Ma 2009a; Li 2012a). The clinical
heterogeneity, which we have documented in the ’Characteristics
of included studies’ table, was high among these studies, especially
regarding the interventions used. We therefore subgrouped the
analyses by co-intervention (see Analysis 1.1 and Analysis 2.1).
1. CHM versus clomiphene
Two studies made this comparison (Li 2007; Ye 2007); one of
these studies administered LOD in both arms (Ye 2007).
Primary outcome
1.1 Live birth rate
None of the included studies reported this outcome.
Secondary outcomes
1.2 Pregnancy rate
When we combined the studies, there was no evidence of a differ-
ence between CHM versus clomiphene (with or without LOD in
both arms) (odds ratio (OR) 1.98, 95% confidence interval (CI)
0.78 to 5.06; two studies, 90 participants, I² statistic = 0%, very
low quality evidence). See Analysis 1.1.
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1.3 Ovulation rate
There was no evidence of a difference between CHM versus
clomiphene (OR 1.42, 95% CI 0.19 to 10.49; one study, 30 par-
ticipants). See Analysis 1.2.
1.4 Adverse events
None of the included studies reported this outcome.
2. CHM + clomiphene versus clomiphene
Three studies made this comparison (Li 2007; Ma 2009a; Li
2012a); one of the studies administered ethinyloestradiol cypro-
terone acetate in both study arms (Ma 2009a).
Primary outcome
2.1 Live birth rate
None of the included studies reported this outcome.
Secondary outcomes
2.2 Pregnancy rate
There was a higher rate of pregnancy in the CHM plus clomiphene
group (OR 2.62, 95% CI 1.65 to 4.14; three studies, 300 partici-
pants, I² statistic = 0%, low quality evidence). See Analysis 2.1 and
Figure 4.
Figure 4. Forest plot of comparison: 3 CHM + clomiphene versus clomiphene, outcome: 3.1 Pregnancy rate
(per woman).
2.3 Ovulation rate
None of the included studies reported this outcome.
2.4 Adverse events
None of the included studies reported this outcome.
3. CHM + follicle aspiration + ovulation induction
versus follicle aspiration + ovulation induction
One study made this comparison (Liang 2008).
Primary outcome
3.1 Live birth rate
Liang 2008 did not report this outcome.
Secondary outcomes
3.2 Pregnancy rate
There was no evidence of a difference between the two groups
(OR 1.60, 95% CI 0.46 to 5.52; one study, 44 women, very low
quality evidence). See Analysis 3.1.
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3.3 Ovulation rate
Liang 2008 did not report this outcome.
3.4 Adverse events
Only one study reported adverse events (Liang 2008). There was
no evidence of a difference between CHM plus follicle aspiration,
ovulation induction and follicle aspiration plus ovulation induc-
tion for LUFS (OR 0.60, 95% CI 0.06 to 6.14; one study, 44
women, very low quality evidence), OHSS (OR 0.16, 95% CI 0.00
to 8.19; one study, 44 women, very low quality evidence) or mul-
tiple pregnancy (OR 0.60, 95% CI 0.06 to 6.14; one study, 44
women, very low quality evidence). See Analysis 3.2, Analysis 3.3
and Analysis 3.4. The severity of adverse events was not reported
and no other data on adverse events were available.
4. CHM + LOD versus LOD
One study made this comparison (Ye 2007).
Primary outcome
4.1 Live birth rate
Ye 2007 did not report this outcome.
Secondary outcomes
4.2 Pregnancy rate
There was no evidence of a difference between the groups (OR
3.5, 95% CI 0.72 to 17.09; one study, 30 women, very low quality
evidence). See Analysis 4.1.
4.3 Ovulation rate
There was no evidence of a difference between the groups (OR
2.43, 95% CI 0.39 to 15.08; one study, 30 women). See Analysis
4.2.
4.4 Adverse events
Ye 2007 did not report this outcome.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
CHM + clomiphene compared to clomiphene for subfertile women with PCOS
Population: subfert ile women with PCOS
Setting: f ert il ity clinics
Intervention: Chinese herbal medicine (CHM) + clomiphene
Comparison: clomiphene




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Clomiphene CHM + clomiphene
Live birth Not reported
Pregnancy rate (per
woman)








Adverse events Not reported
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relat ive ef fect of the intervent ion (and its 95% CI)
Abbreviat ions: CI: conf idence interval; OR: odds rat io.
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Downgraded one level for serious risk of bias: study methods not described in suf f icient detail.












































































































CHM + follicle aspiration + ovulation induction compared to follicle aspiration + ovulation induction for subfertile women with PCOS
Population: subfert ile women with PCOS
Setting: f ert il ity clinics
Intervention: Chinese herbal medicine + follicle aspirat ion + ovulat ion induct ion
Comparison: f ollicle aspirat ion + ovulat ion induct ion




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Follicle aspiration +
ovulation induction
CHM + follicle aspira-
tion + ovulation induc-
tion
Live birth Not reported




















t ion syndrome (adverse
events)








Mult iple pregnancy (ad-
verse events)








* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relat ive ef fect of the intervent ion (and its 95% CI)












































































































GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Downgraded one level for serious risk of bias: the study authors did not report the study methods in suf f icient detail, and the
study authors did not describe the allocat ion concealment method.
2Downgraded two levels for very serious imprecision: small study, few events, CIs compatible with no ef fect or with substant ial













































































































CHM + LOD compared to LOD for subfertile women with PCOS
Population: subfert ile women with PCOS
Setting: f ert il ity clinics
Intervention: CHM + LOD
Comparison: LOD




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
LOD CHM + LOD
Live birth Not reported
Pregnancy rate (per
woman)








Adverse events Not reported
* The basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison
group and the relat ive ef fect of the intervent ion (and its 95% CI)
Abbreviat ions: CI: conf idence interval; OR: odds rat io
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1Downgraded one level for serious risk of bias: the study authors did not report the study methods in suf f icient detail.
2Downgraded two levels for very serious imprecision: small study, few events, and CIs were compatible with no ef fect or with












































































































D I S C U S S I O N
Summary of main results
There is insufficient evidence to support the use of CHM in treat-
ing women with polycystic ovarian syndrome (PCOS) and sub-
fertility. None of the included studies reported live birth rate, and
only very limited data were available for the other review out-
comes.
There was very limited evidence to suggest the following.
1. For women with PCOS and infertility, the efficacy of
clomiphene in improving pregnancy rate (per woman), with or
without pretreatment of ethinyloestradiol cyproterone acetate,
may be enhanced by Chinese herbal medicine (CHM). Inversely,
that of CHM may not be enhanced by clomiphene.
2. For women with PCOS, infertility and resistance to
Western drugs of ovulation induction, the efficacy of follicle
aspiration or laparoscopic ovarian drilling (LOD) in improving
pregnancy rate may not be strengthened by CHM. This may
indicate that women resistant to Western drugs of ovulation
induction may also be resistant to CHM of ovulation induction.
3. For women with PCOS, infertility and resistance to
ovulation induction, there is not enough evidence to support the
use of CHM in improving ovulation rate.
4. Only one included study reported adverse events, including
luteinized unruptured follicle syndrome (LUFS), ovarian
hyperstimulation syndrome (OHSS) and multiple pregnancy,
but did not indicate the severity of the adverse events. None of
the included studies reported some of the adverse events thought
to be associated with CHM (e.g. impairment of liver and kidney,
allergies). Therefore, the safety of CHM for women with PCOS
and subfertility remains unclear.
There was very limited evidence that the addition of CHM to
clomiphene was associated with improved clinical pregnancy out-
comes but no other evidence of any other effect. This finding re-
quires extremely cautious interpretation.
Overall completeness and applicability of
evidence
The included studies only partially addressed the objectives of this
review. We were unable to reach definite conclusions due to the
lack of data for each comparison group. The high heterogeneity
of CHM preparations in the included studies may limit the gen-
eralizability of the results regarding the effectiveness of CHM for
subfertile women with PCOS in general. The included studies
failed to report the most important outcome, which is live birth
rate. Future studies should report major clinical outcomes such as
live birth, clinical pregnancy and adverse events.
The included studies were clinically heterogeneous and differed
in (or failed to report) factors such as the duration of treatment,
CHM formula, dosage and length of follow-up. Moreover no stud-
ies compared CHM with the first-line interventions for PCOS,
such as diet control and exercise. These interventions should be
compared with CHM in future studies.
Quality of the evidence
The quality of the evidence for most comparisons was very low.
The main limitations in the evidence were failure to report live
birth or adverse events, failure to describe study methods in ade-
quate detail and imprecision, with very low event rates and wide
confidence intervals (CIs).
None of the included studies clearly reported blinding or described
their method of allocation concealment, and some did not clearly
report drop-out rates. Only one included study used placebo drugs
(Li 2007), so the study may have used blinding. However, we were
unable to obtain detailed information from the study authors.
Protocols were not registered in clinical trial registers, so we could
not evaluate the risk of selective reporting bias.
Potential biases in the review process
In order to limit bias in the review process, the Cochrane Gy-
naecology and Fertility Group guided and developed the litera-
ture search. We did not apply any restrictions on language to the
searches. Two review authors (ZK, ZJ) independently performed
study selection, ’Risk of bias’ assessments and data collection but
without blinding. We resolved any disagreements by discussion
with a third review author (WT). We attempted to obtain missing
information and data by contacting the primary study authors but
were not always successful. Thus, we excluded those studies that
we could not classified as randomized controlled trials (RCTs) due
to lack of information.
In our review, we performed intention-to-treat (ITT) analyses by
assuming failure for drop-outs in treatment group and success for
drop-outs in the control group.
The review authors had no conflicts of interest.
Agreements and disagreements with other
studies or reviews
In the future, well-designed RCTs with large sample size are war-
ranted to confirm or refute the current evidence. There are no other
systematic reviews on CHM for subfertile women with PCOS.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to support the use of CHM for
women with PCOS and subfertility. No data are available on live
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birth, and there is no consistent evidence to indicate that CHM im-
proves fertility outcomes. However there is very limited low qual-
ity evidence to suggest that the addition of CHM to clomiphene
may improve pregnancy rates. There is insufficient evidence on
adverse effects to indicate whether CHM is safe.
Implications for research
Study authors should report methodology in detail, such as ran-
domization and allocation concealment methods. Well-designed
and well-conducted RCTs with double blinding should be con-
ducted. The duration of follow-up for assessing outcomes should
also be reported. The CHM formula and dosage should be re-
ported. Future research should expand sample size, evaluate live
birth rate and other safety indexes. Interventions for PCOS, such
as diet control and exercise, should be compared with CHM in
future studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Li 2007
Methods RCT, single centre, 90 participants, 3 years’ duration
Participants 90 enrolled: CHM 1 = 30, CHM 2 = 30, control = 30, 21 to 38 years, baseline were
comparable
87 analysed/evaluated: CHM1 = 29 (1 converted to IVF-ET after CHM treating for 1
month), CHM2 = 30, control = 28 (1 moved to other place, 1 discontinued therapy
because of pelvic inflammation)
Obesity: CHM1 = 7, CHM2 = 6, control = 6
Hirsutism: CHM1 = 19, CHM2 = 18, control = 21
LH/FSH > 2.5: CHM1 = 20, CHM2 = 19, control = 21
High testosterone: CHM1 = 16, CHM2 = 17, control = 15
Follicle number > 10: CHM1 = 25, CHM2 = 24, control = 22
Enlarged ovary: CHM1 = 5, CHM2 = 6, control = 7
PCOS DC: consistent with Rotterdam criteria (evaluated by review authors)
In: PCOS and infertility
Ex: using other drugs of ovulation induction, participants unable to follow-up, tumour
patients, adrenal diseases, other hyper androgenic diseases
Interventions CHM1: clomiphene simulacrum (5 to 9 day of menstrual cycle, 1 pill, once a day, 5 days)
, Lingzhu infusion (5 to 14 day of menstrual cycle, 1 bag, tid, 10 days), Shenqi capsule
(from 14th day of menstrual cycle or after ovulation, 4 grains, tid, until menstrual onset
or pregnancy or the 45th day of menstrual cycle), if amenorrhoea for 45 days then MPA
would be prescribed (10 mg, once a day, 5 days)
CHM2: clomiphene (5 to 9 day of menstrual cycle, 50 mg, once a day, 5 days), Lingzhu
infusion, Shenqi capsule, and MPA
Control: clomiphene, Lingzhu simulacrum, Shenqi simulacrum, and MPA
Duration: treated no more than 6 menstrual cycles, follow-up time was unclear
Outcomes LH, testosterone, LH/FSH, estradiol, insulin, BMI, cervical mucus
Pregnancy rate (per woman)
Ovulation rate (per cycle)
Notes Clomiphene: Codal Synto Ltd. batch number: H20020325
Lingzhu infusion: hospital preparation, batch number Z03020211, 6 g/bag
Shenqi capsule: hospital preparation, batch number Z03020212, 0.5 g/pill
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk We were unable to contact the study au-
thors for more information
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Li 2007 (Continued)
Allocation concealment (selection bias) Unclear risk We were unable to contact the study au-
thors for more information
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study used mimic drugs. Participants
and the outcome assessor were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No intention-to-treat (ITT) analysis. The
analysis rate was 96.7% (87/90)
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable
Other bias Low risk No other potential risk of bias identified
Li 2012a
Methods RCT, single centre, 70 participants, 1 year duration
Participants 70 enrolled: CHM = 35, control = 35, 22 to 39 years, baseline were comparable
70 analysed/evaluated: CHM = 35, control = 35
Age (years): CHM 28.5 ± 3.8, control 26.2 ± 3.6
Subfertility time (years): CHM 5 ± 2.7, control 4.6 ± 2.4
PCOS DC: consistent with Rotterdam criteria (evaluated by review authors)
In: PCOS, infertility, 20 to 40 years
Ex: using hormone or drugs of ovulation induction in the last 3 months, tubal infertility,
uterine infertility, male sterility
Interventions CHM: Xuanju capsule (day 3 of menstrual cycle, 3 pills, tid, 4 weeks), clomiphene (day
3 of menstrual cycle, 50 mg, once a day, 5 days), HCG was injected when dominant
follicle was present, if dominant follicle was absent until the 20 day of menstrual cycle,
progesterone was injected 20 mg, once a day, 5 days
Control: clomiphene (day 3 of menstrual cycle, 50 mg, once a day, 5 days), HCG was
injected when dominant follicle was present, if dominant follicle was absent until the 20
day of menstrual cycle, progesterone was injected 20 mg, once a day, 5 days
Duration: treatment until pregnancy but no more than 3 cycles; follow-up duration was
unclear
Outcomes Pregnancy rate (per woman)
Ovulation rate (per cycle)
Notes Xuanju capsule: Zhejiang Shiqiang Pharmaceutical Company, batch number:
Z20060462
Risk of bias
Bias Authors’ judgement Support for judgement
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Li 2012a (Continued)
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk We were unable to contact the study au-
thors for more information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk We were unable to contact the study au-
thors for more information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawal or drop-out was reported.
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable.
Other bias Low risk No other potential risk of bias identified
Liang 2008
Methods RCT, 2 clinical centres, 44 participants, 1 year duration
Participants 44 enrolled: CHM = 20, control = 24, baseline was comparable
44 analysed/evaluated: CHM = 20, control = 24
40 ovulation induction: CHM = 18, control = 22 (follicle aspiration was ineffective for
4)
Age (years): CHM 27.4 ± 2.7, control 27.1 ± 3.2
Subfertility time (years): CHM 2.10 ± 0.97, control 2.0 ± 0.84
BMI (kg/m²): CHM 24.2 ± 2.9, control 25.2 ± 3.1
PCOS DC: 2003 Rotterdam criteria
In: PCOS patients with infertility and clomiphene resistance (clomiphene 150 mg/d, 5
d/month, 3 months, but without follicle growth)
Ex: other endocrinology diseases, tubal infertility, male sterility
Interventions CHM interventions: Bushen Huoxue formula combined with ultrasound guided follicle
aspiration and ovulation induction
Control interventions: ultrasound guided follicle aspiration and ovulation induction
Ultrasound guided follicle aspiration: on 10th to 12th day of menstrual cycle, 36 hours
after HCG (10000 IU) injection, bilateral ovaries, 2 to 4 times of inserting per ovary,
once a month until presence of efficacy but no more than 3 months (efficacy was defined
as testosterone < 1.6 nmol/L, LH/FSH < 2, number of antral follicle in each ovary were
less than 10 at early follicle phase of the following menstrual cycle)
Bushen Huoxue formula: from 5th day of menstrual cycle, 1 dose/day, 14 days
Ovulation induction: after effective follicle aspiration, no more than 3 cycles, human
menopausal gonadotrophin (HMG) (from 5th day of menstrual cycle, 15 to 150IU/d,
until presence of dominant follicle), then HCG (5000 to 10000 IU)
Duration: treatment: no more than 6 menstrual cycles, follow-up: 3 months after ovu-
lation induction
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Liang 2008 (Continued)
Outcomes FSH, LH, testosterone
Number of antral follicle
Pregnancy rate (per woman)
Dosage of HMG
Side effects: LUFS, OHSS, multiple pregnancy
Number of mature follicles
Notes Blood hormone level and ultrasound were usually measured at 3rd day of menstrual cycle
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) High risk Random number was open
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding. We contacted the study au-
thor for this information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No ITT analysis. The analysis rate was 90.
9% (40/44)
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable
Other bias Low risk No other potential risk of bias identified
Ma 2009a
Methods RCT, single centre, 170 participants, 4 years’ duration
Participants 170 enrolled: CHM = 85, control = 85, baseline was comparable
165 analysed/evaluated: CHM = 85, control = 80 (5 withdrawals for personal reasons)
Age (years): CHM: 28.4 ± 5.3, control: 27.9 ± 4.9
Infertility time (years): CHM: 3.8 ± 2.1, control: 3.6 ± 1.9
PCOS DC: 2003 Rotterdam criteria
In: PCOS and infertility
Ex: other endocrinology diseases, hormone user in the last 3 months, male infertility,
tubal infertility
Interventions CHM: CHM combined with ethinyloestradiol cyproterone acetate and ovulation in-
duction
Control: CEA following with ovulation induction
CHM: basic formula in CEA therapy duration, CHM periodic therapy in ovulation
induction phase (gui shao di huang soup in 5th to 14th day of menstrual cycle, tao hong
si wu soup in 12th to 16th day of menstrual cycle, shou tai pellet after ovulation)
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CEA: from 5th day of menstrual cycle, 1 pill, once a day, 21 days/m, treated for 3 cycles
and then ovulation induction
ovulation induction: clomiphene (from 5th day of menstrual cycle, 50 mg, once a day,
5 days/m), 5000 to 10000 IU HCG was injected when dominant follicle was present,
ovulation induction until pregnancy but no more than 3 cycles
Duration: treatment: no more than 6 menstrual cycles, follow-up time was unclear
Outcomes Ovulation rate (per cycle)
Pregnancy rate (per woman)
Miscarriage rate
Notes Ethinyloestradiol cyproterone acetate: Germany Schering company, batch number:
G20040104
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk We contacted the study author who de-
clined to provide related information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk We contacted the study author who de-
clined to provide related information
Incomplete outcome data (attrition bias)
All outcomes
Low risk No ITT analysis. The analysis rate was 97.
1% (165/170)
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable
Other bias Low risk No other potential risk of bias identified
Ye 2007
Methods RCT, single centre, 40 participants, 20 months’ duration
Participants 40 enrolled: CHM = 20, control 1 = 10, control 2 = 10, baseline were comparable, 27.
4 ± 2.7 years
40 analysed/evaluated: CHM = 20, control 1 = 10, control 2 = 10
PCOS DC: 2003 Rotterdam criteria
In: PCOS and infertility and resistance to ovulation induction drugs
Ex: tubal infertility, male infertility, malformation of genital organ, immunological in-
fertility
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Interventions CHM: CHM periodic therapy combined with laparoscopic ovary drilling
Control 1: clomiphene combined with laparoscopic ovary drilling
Control 2: laparoscopic ovary drilling
Duration: treatment: 6 months, follow-up: 1 year
Clomiphene: 50 mg, once a day, 5d/m (if without efficacy, add 50 mg, maximum 150
mg/d)
Outcomes LH, FSH, testosterone
Ovulation rate (per woman)
Pregnancy rate (per woman)
Notes Laparoscopic ovary drilling: 8 to 10 holes per ovary, injected 300 mL of low molecular
dextran or 4 mL of sodium hyaluronate in abdomen after surgery
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk We contacted the study author who refused
to provide related information
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk We contacted the study author who refused
to provide related information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawal or drop-out was reported.
Selective reporting (reporting bias) Unclear risk The study protocol was unavailable.
Other bias Low risk No other potential risk of bias identified
Abbreviations: CHM: Chinese herbal medicine, BMI: body mass index, PCOS: polycystic ovarian syndrome, DC: diagnosis criteria,
In: inclusion criteria, Ex: exclusion criteria, HCG: human chorionic gonadotrophin, HMG: human menopausal gonadotropin,
LH: luteinizing hormone, FSH: follicle stimulating hormone, LUFS: luteinized unruptured follicle syndrome, OHSS: ovarian
hyperstimulation syndrome, ITT: intention to treat, MPA: medroxyprogesterone acetate, CEA: ethinyloestradiol cyproterone acetate.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
An 2009 No outcomes of interest
An 2012 Diagnosis is inconsistent with Rotterdam criteria
Arentz 2014 Review
Bablis 2006 Case report
Bai 2011 Non-randomized controlled trials (RCTs)
Bao 2009 No outcomes of interest; polycystic ovarian syndrome (PCOS) with or without infertility in this
study
Bao 2014 No Chinese herbal medicine (CHM) intervention
Bei 2010 Non-RCT, which the primary study authors confirmed
Cai 2006 Adolescent PCOS without infertility; no outcomes of interest
Cai 2011 Quasi-RCT, which the primary study authors confirmed
Cai 2012 PCOS diagnosis is inconsistent with Rotterdam criteria
Cai 2014 Not a RCT
Cao 2010 Non-RCT, which the primary study authors confirmed
Cao 2012 Non-RCT, which the primary study authors confirmed
Chan 2006a No outcomes of interest; PCOS with or without infertility
Chan 2006b Non-CHM intervention
Chen 2005 PCOS with or without infertility in this study
Chen 2006a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Chen 2006b PCOS with or without infertility in this study
Chen 2007 Intervention with acupuncture but without herbal medicine
Chen 2008 No outcomes of interest; PCOS with or without infertility in this study
Chen 2009 Intervention with acupuncture but without herbal medicine
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Chen 2010a No outcomes of interest
Chen 2010b No outcomes of interest
Chen 2011a No outcomes of interest; PCOS with or without infertility
Chen 2011b No outcomes of interest; PCOS with or without infertility
Chen 2011c Quasi-RCT
Chen 2012a No outcomes of interest; PCOS with or without infertility
Chen 2012b No outcomes of interest; PCOS with or without infertility
Chen 2012c Quasi-RCT
Chen 2012d PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Chen 2013 Non-PCOS participants
Chen 2014a Quasi-RCT
Chen 2014b Not a RCT
Chen 2014c Non-CHM intervention
Chen 2015 Participants had no wish to conceive
Chen 2016 Non-CHM intervention
Cheng 2009 No outcomes of interest; PCOS with or without infertility in this study
Cheng 2014 Non-CHM intervention
Cheng 2015 Participants had no wish to conceive
Chu 2013 Non-PCOS participants
Craig 2015 Non-CHM intervention
Cui 2012 PCOS with or without infertility; no outcomes of interest
Dang 2012 Non-RCT, which the primary authors confirmed
Deng 2008 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Deveci 2015 Non-CHM intervention
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Ding 2015 Unrelated study
Dong 2009 No outcomes of interest
Dong 2010 No outcomes of interest
Du 2012 PCOS with or without infertility; no outcomes of interest
Du 2013 Participants had no wish to conceive
Fang 2004 No outcomes of interest
Feng 2009a No outcomes of interest; PCOS with or without infertility in this study
Feng 2009b No outcomes of interest; PCOS with or without infertility
Feng 2011a Non-RCT confirmed by primary authors
Feng 2011b Quasi-RCT
Fu 2012 PCOS diagnosis is inconsistent with Rotterdam criteria; PCOS with or without infertility in this
study; no outcomes of interest
Gao 2009 Intervention with acupuncture but without herbal medicine
Gao 2011a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Gao 2011b PCOS with or without infertility in this study
Ghavi 2015 With or without subfertility
Gong 2012 PCOS with or without infertility in this study
Grant 2010 No outcomes of interest; PCOS with or without infertility
Gu 2015 Participants had no wish to conceive
Guo 2008 No outcomes of interest; PCOS with or without infertility
Guo 2009 PCOS with or without infertility in this study
Guo 2011a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Guo 2011b No outcomes of interest; PCOS with or without infertility in this study
Haj-Husein 2016 With or without subfertility
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Han 2008 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Han 2011 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Han 2013a Participants had no wish to conceive
Han 2013b Not a RCT
Han 2015 Not a RCT
Hao 2012 Quasi-RCT, which the primary authors confirmed
Harman 2001 Non-PCOS
Hassanzadeh Bashtian 2013 Participants had no wish to conceive
He 2009 PCOS with or without infertility in this study
He 2010 Quasi-RCT
He 2014 Quasi-RCT
Hou 2000 No outcomes of interest
Hu 2009a Intervention with acupuncture but without herbal medicine; PCOS with and without infertility
Hu 2009b Intervention with acupuncture but without herbal medicine
Hu 2014 Participants had no wish to conceive
Hua 2003 Case control study
Huang 2004 Quasi-RCT confirmed by primary authors
Huang 2006a Non-RCT confirmed by primary authors
Huang 2006b PCOS without infertility; quasi-RCT; No outcomes of interest
Huang 2007 PCOS with or without infertility in this study
Huang 2008 Review
Huang 2010 Quasi-RCT
Huang 2011a No outcomes of interest
Huang 2011b No outcomes of interest
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Huang 2012a No outcomes of interest; PCOS with or without infertility
Huang 2012b PCOS diagnosis is inconsistent with Rotterdam criteria
Hung 2016 Cohort study
Huo 2008 Unrelated
Jalilian 2013 Non-CHM intervention
Jia 2004 Diagnosis inconsistent with Rotterdam; quasi-RCT
Jia 2008 Concurrent control study
Jia 2010 PCOS with or without infertility; PCOS diagnosis is inconsistent with Rotterdam criteria
Jia 2012a No outcomes of interest
Jia 2012b PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT; no outcomes of interest;
PCOS with or without infertility
Jian 2011 No outcomes of interest
Jiang 2007 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Jiang 2011a No outcomes of interest; PCOS with or without infertility
Jiang 2011b No outcomes of interest; PCOS with or without infertility
Jiang 2014 Non-PCOS participants
Jiang 2015 Non-CHM intervention
Jin 2014a Quasi-RCT
Jin 2014b Non-CHM intervention
Jin 2016 Participants had no wish to conceive
Johnson 2015 Non-CHM intervention
Kang 2012 No outcomes of interest; PCOS with or without infertility
Kawakami 2011 Unrelated
Kitagawa 2015 Non-PCOS participants
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Kort 2014 With or without subfertility
Kuang 2012 Quasi-RCT, which the primary authors confirmed
Kuang 2013 Non-CHM intervention
Kuang 2015 Non-CHM intervention
Kuek 2011 No outcomes of interest; PCOS with or without infertility in this study
Lai 2006 No outcomes of interest; PCOS with or without infertility; PCOS diagnosis is inconsistent with
Rotterdam criteria
Lai 2011 Quasi-RCT
Lai 2014a Participants had no wish to conceive
Lai 2014b Participants had no wish to conceive
Lai 2014c Participants had no wish to conceive
Lai 2015a Review
Lai 2015b Participants had no wish to conceive
Lai 2015c Participants had no wish to conceive
Lai 2015d Participants had no wish to conceive
León-Gonzalez 2014 Unrelated
Li 2000 PCOS with or without infertility in this study
Li 2002 PCOS diagnosis is inconsistent with Rotterdam criteria
Li 2005 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Li 2009a No outcomes of interest
Li 2009b PCOS without infertility
Li 2009c Duplication
Li 2009d No outcomes of interest; PCOS with or without infertility
Li 2010a No outcomes of interest; PCOS with or without infertility; PCOS diagnosis is inconsistent with
Rotterdam criteria
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Li 2010b No outcomes of interest; PCOS with or without infertility
Li 2010c PCOS diagnosis is inconsistent with Rotterdam criteria
Li 2010d No outcomes of interest; PCOS with or without infertility
Li 2011a No outcomes of interest
Li 2011b Participants had no wish to conceive
Li 2011c PCOS with or without infertility; no outcomes of interest
Li 2011d No outcomes of interest; PCOS with or without infertility
Li 2011e No outcomes of interest; PCOS with or without infertility; PCOS diagnosis is inconsistent with
Rotterdam criteria
Li 2011f PCOS with or without infertility in this study
Li 2011g No outcomes of interest
Li 2011h No outcomes of interest; PCOS with or without infertility
Li 2011i No outcomes of interest; PCOS with or without infertility
Li 2011j PCOS diagnosis is inconsistent with Rotterdam criteria
Li 2011k No outcomes of interest
Li 2012b No outcomes of interest
Li 2012c No outcomes of interest; PCOS with or without infertility
Li 2013a Non-CHM intervention
Li 2013b Participants had no wish to conceive; protocol
Li 2015 Non-CHM intervention




Liao 2014 Non-CHM intervention
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Lim 2011 Review
Lin 2005 Non-RCT, which the primary authors confirmed
Lin 2009a Non-RCT, which was confirmed by the author
Lin 2009b Quasi-RCT
Lin 2011 We were unable to contact the study authors for the detailed information about the laparoscopic
surgery method
Lin 2013a Participants had no wish to conceive
Lin 2013b Participants had no wish to conceive
Lin 2013c Participants had no wish to conceive
Liu 2007 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Liu 2008 Unrelated
Liu 2009 Diagnosis inconsistent with Rotterdam; quasi-RCT
Liu 2010a Quasi-RCT
Liu 2010b Non-RCT, which the primary study authors confirmed
Liu 2010c No outcomes of interest; PCOS with or without infertility
Liu 2010d No outcomes of interest; PCOS with or without infertility
Liu 2011a Quasi-RCT
Liu 2011b Quasi-RCT; no outcomes of interest; PCOS with or without infertility
Liu 2012a No outcomes of interest
Liu 2012b No outcomes of interest
Liu 2012c No outcomes of interest
Liu 2013 Quasi-RCT
Liu 2014a Participants had no wish to conceive
Liu 2014b Participants had no wish to conceive
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Lu 2010 PCOS diagnosis is inconsistent with Rotterdam criteria
Lu 2012 Diagnosis inconsistent with Rotterdam; quasi-RCT
Luo 2010 No outcomes of interest
Luo 2014 Not a RCT
Lv 2007 Intervention with acupuncture but without herbal medicine
Lv 2009 No outcomes of interest; PCOS with or without infertility in this study
Lv 2010 No outcomes of interest; PCOS with or without infertility in this study
Ma 2009b Quasi-RCT
Ma 2010 No outcomes of interest
Madder 2013 Review
Mao 2003 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Mao 2011a No outcomes of interest
Mao 2011b Non-RCT, which the primary authors confirmed
Mei 2010 PCOS with or without infertility
Meng 2011 No outcomes of interest; part of the study was about animals
Miao 2012 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT; PCOS diagnosis is incon-
sistent with Rotterdam criteria
Ming-Wei 2011 Non-PCOS participants
Mohammad Hosseinzadeh 2016 Non-CHM intervention
Moradan 2012 Review




Pan 2010 No outcomes of interest
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Pan 2012 No outcomes of interest
Pastore 2011 Non-CHM intervention
Pazyar 2012 Unrelated study
Pei 2012 PCOS with or without infertility in this study
Peng 2012 No outcomes of interest
Qiao 2012 Quasi-RCT
Qiu 2006 No outcomes of interest; PCOS with or without infertility in this study
Qu 2015 Unrelated
Qv 2011 PCOS with or without infertility
Ran 2007a No outcomes of interest
Ran 2007b Case control study
Ran 2008 Case control study
Rao 2012 No PCOS
Rashidi 2013 Non CHM intervention
Ren 2002a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Ren 2002b Duplication
Ren 2006 No outcomes of interest; PCOS with or without infertility
Ren 2008 No outcomes of interest; PCOS with or without infertility
Ren 2011 PCOS with or without infertility




Salah 2013 Non-CHM intervention
59Chinese herbal medicine for subfertile women with polycystic ovarian syndrome (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
See 2011 SR
Shah 2016 Non-CHM intervention
Shao 2004 PCOS diagnosis is inconsistent with Rotterdam criteria
Shao 2006 PCOS diagnosis is inconsistent with Rotterdam criteria
Shen 2008 PCOS diagnosis is inconsistent with Rotterdam criteria
Shen 2013 Participants were not subfertile
Sheng 2010 No outcomes of interest; PCOS with or without infertility
Shi 2009a No outcomes of interest; PCOS with or without infertility in this study
Shi 2009b No outcomes of interest; PCOS with or without infertility in this study
Shi 2010a PCOS with or without infertility
Shi 2010b No outcomes of interest
Shi 2011 PCOS with or without infertility; PCOS diagnosis is inconsistent with Rotterdam criteria
Shu 2012 No outcomes of interest
Si 2016 Participants had no wish to conceive
Song 2010 No outcomes of interest; PCOS with or without infertility
Song 2011 PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest
Stone 2009 Case report
Su 2012 No outcomes of interest; PCOS with or without infertility
Sui 2011 PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest
Sun 2009a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Sun 2009b No outcomes of interest
Sun 2010a PCOS with or without infertility
Sun 2010b Intervention with acupuncture but without herbal medicine
Sun 2011 PCOS with or without infertility
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Sun 2012 PCOS with or without infertility; quasi-RCT
Sun 2014 No CHM intervention
Tan 2005 Diagnosis inconsistent with Rotterdam; quasi-RCT
Tan 2012 SR
Tang 2012 No outcomes of interest; PCOS with or without infertility
Tao 2003 Diagnosis inconsistent with Rotterdam; PCOS with or without infertility
Tao 2006 Concurrent control study
Tao 2008 No outcomes of interest; PCOS with or without infertility in this study
Tao 2009 No outcomes of interest; PCOS with or without infertility in this study
Tao 2010 No outcomes of interest; PCOS with or without infertility
Tao 2011 No outcomes of interest; PCOS with or without infertility
Ulbricht 2016 SR
Ushiroyama 2001 Diagnosis inconsistent with Rotterdam, participants including PCOS and non-PCOS
Ushiroyama 2006 Diagnosis inconsistent with Rotterdam
Vajda 2013 Not a RCT
van Oppen 2015 Non-PCOS
Wan 2012 No outcomes of interest; PCOS with or without infertility
Wang 2005a PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Wang 2005b Before-and-after study
Wang 2006a PCOS with or without infertility in this study
Wang 2006b Quasi-RCT
Wang 2009 Intervention with acupuncture but without herbal medicine
Wang 2010a PCOS with or without infertility; quasi-RCT
Wang 2010b No outcomes of interest; PCOS with or without infertility
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Wang 2011a PCOS with or without infertility
Wang 2011b Quasi-RCT
Wang 2011c No outcomes of interest; PCOS with or without infertility
Wang 2011d No outcomes of interest
Wang 2012a PCOS with or without infertility
Wang 2012b PCOS with or without infertility; quasi-RCT
Wang 2013 No CHM intervention
Wang 2016 No CHM intervention
Wei 2008 PCOS diagnosis is inconsistent with Rotterdam criteria
Wei 2011a No outcomes of interest; PCOS with or without infertility
Wei 2011b PCOS diagnosis is inconsistent with Rotterdam criteria; PCOS with or without infertility in this
study
Wei 2011c No outcomes of interest; PCOS with or without infertility; diagnosis inconsistent with Rotterdam
criteria
Wu 2008 PCOS with or without infertility in this study
Wu 2010a No outcomes of interest; PCOS with or without infertility in this study
Wu 2010b PCOS diagnosis is inconsistent with Rotterdam criteria
Wu 2011 PCOS with or without infertility in this study
Wu 2012a PCOS with or without infertility; no outcomes of interest
Wu 2012b Non-CHM intervention
Wu 2013a No CHM intervention
Wu 2013b Non-PCOS participants
Wuttke 2015 Non-PCOS participants
Xia 2004 No outcomes of interest
Xia 2007 Quasi-RCT
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Xia 2011 PCOS diagnosis is inconsistent with Rotterdam criteria
Xiao 2014 No CHM intervention
Xie 2005 Diagnosis inconsistent with Rotterdam criteria
Xie 2010 PCOS with or without infertility
Xie 2012 PCOS with or without infertility
Xiong 2012 No outcomes of interest; PCOS with or without infertility
Xu 2008a PCOS with or without infertility
Xu 2008b Diagnosis inconsistent with Rotterdam criteria; quasi-RCT
Xu 2009 PCOS with or without infertility in this study
Xu 2010a No outcomes of interest
Xu 2010b PCOS with or without infertility
Xu 2012 No outcomes of interest; PCOS with or without infertility
Xu 2016 Participants had no wish to conceive
Xue 2004 Diagnosis inconsistent with Rotterdam criteria; quasi-RCT
Yan 2003 Duplication
Yan 2005 PCOS diagnosis is inconsistent with Rotterdam criteria
Yan 2012 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Yang 2005 Intervention with acupuncture but without herbal medicine
Yang 2008 Animal study
Yang 2010a No outcomes of interest; PCOS with or without infertility in this study
Yang 2010b PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest; PCOS with or
without infertility
Yang 2010c No outcomes of interest; quasi-RCT
Yang 2011 PCOS diagnosis is inconsistent with Rotterdam criteria; PCOS with or without infertility in this
study
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Yang 2014a No CHM intervention
Yang 2014b Participants had no wish to conceive
Yang 2015 No CHM intervention
Yao 2011 No outcomes of interest; PCOS with or without infertility
Yao 2012a PCOS with or without infertility
Yao 2012b Quasi-RCT; no outcomes of interest
Ye 2004 PCOS with or without infertility; diagnosis inconsistent with Rotterdam criteria
Ye 2010 PCOS with or without infertility; no outcomes of interest
Ye 2012a PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest; quasi-RCT
Ye 2012b No outcomes of interest
Ye 2015 Participants had no wish to conceive
Yi 2012 PCOS with or without infertility
Yin 2007 Laparoscopic ovary wedgeshaped resection was used in this study
Yu 2013 With or without subfertility
Yu 2015 Participants had no wish to conceive
Yuan 2011 No outcomes of interest
Yv 2011 No outcomes of interest; PCOS with or without infertility
Zeng 2007 PCOS diagnosis is inconsistent with Rotterdam criteria; quasi-RCT
Zeng 2012 No interventions of interest
Zhang 2003a No outcomes of interest; PCOS with or without infertility;diagnosis inconsistent with Rotter-
dam;quasi-RCT
Zhang 2003b Concurrent control study
Zhang 2007a No outcomes of interest; PCOS with or without infertility in this study
Zhang 2007b No outcomes of interest; PCOS with or without infertility in this study
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Zhang 2007c PCOS with or without infertility in this study
Zhang 2007d Duplication
Zhang 2009 No outcomes of interest; PCOS with or without infertility in this study
Zhang 2010a PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest
Zhang 2010b No outcomes of interest; PCOS with or without infertility
Zhang 2010c No outcomes of interest
Zhang 2010d No outcomes of interest; PCOS with or without infertility
Zhang 2010e PCOS diagnosis is inconsistent with Rotterdam criteria; no outcomes of interest
Zhang 2011a Not a RCT
Zhang 2011b No outcomes of interest
Zhang 2011c No outcomes of interest; PCOS with or without infertility
Zhang 2011d No outcomes of interest; PCOS with or without infertility
Zhang 2011e Non-RCT, which the primary authors confirmed
Zhang 2011f No outcomes of interest; PCOS with or without infertility
Zhang 2012a No outcomes of interest; PCOS with or without infertility
Zhang 2012b PCOS with or without infertility; no outcomes of interest
Zhang 2012c PCOS with or without infertility; no outcomes of interest
Zhang 2012d No outcomes of interest; quasi-RCT
Zhang 2014a Participants had no wish to conceive
Zhang 2014b Participants had no wish to conceive
Zhang 2015a Participants had no wish to conceive
Zhang 2015b With or without subfertility
Zhang 2015c Participants had no wish to conceive
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Zhang 2015d Animals
Zhao 2006a No outcomes of interest; PCOS with or without infertility in this study
Zhao 2006b Intervention without herbal medicine
Zhao 2006c Intervention without herbal medicine
Zhao 2007 PCOS diagnosis is inconsistent with Rotterdam criteria
Zhao 2008a Quasi-RCT
Zhao 2008b Duplication
Zhao 2008c Intervention without herbal medicine
Zhao 2009 Concurrent control study; PCOS with or without infertility
Zhao 2010a No outcomes of interest
Zhao 2010b Non-RCT confirmed by primary authors
Zhao 2014 No interventions of interest
Zhao 2016 Participants had no wish to conceive
Zheng 2011 No outcomes of interest; PCOS with or without infertility
Zheng 2011a PCOS with or without infertility
Zheng 2011b No outcomes of interest; PCOS with or without infertility
Zheng 2011c PCOS with or without infertility
Zheng 2014a Quasi-RCT
Zheng 2014b Participants had no wish to conceive
Zheng 2015a Quasi-RCT
Zheng 2015b Participants had no wish to conceive
Zhi 2012 No outcomes of interest; PCOS with or without infertility
Zhong 2006 PCOS with or without infertility in this study
Zhong 2008 PCOS with or without infertility
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Zhong 2009a No outcomes of interest; PCOS with or without infertility in this study
Zhong 2009b PCOS with or without infertility in this study
Zhong 2012 Non-RCT, which the primary study authors confirmed
Zhou 1996 PCOS diagnosis is inconsistent with Rotterdam criteria
Zhou 2010a PCOS with or without infertility
Zhou 2010b Non-RCT, which the primary authors confirmed
Zhou 2012a No outcomes of interest
Zhou 2012b No outcomes of interest
Zhou 2012c No outcomes of interest; PCOS with or without infertility






Zhu 2009 Concurrent control study
Zhu 2012a PCOS with or without infertility; no outcomes of interest
Zhu 2012b No outcomes of interest
Zhu 2013a Participants had no wish to conceive
Zhu 2013b Participants had no wish to conceive
Zhu 2014 Quasi-RCT
Zhuang 2008 PCOS diagnosis is inconsistent with Rotterdam criteria
Zou 2012 No outcomes of interest; PCOS with or without infertility; PCOS diagnosis is inconsistent with
Rotterdam criteria
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(Continued)
Zou 2014a Quasi-RCT
Zou 2014b Participants had no wish to conceive
Zuo 2011 No outcomes of interest; PCOS with or without infertility
Abbreviations: RCT: randomized controlled trial, CHM: Chinese herbal medicine, PCOS: polycystic ovarian syndrome, SR: systematic
review.
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-IOR-16008557
Trial name or title The Qilingwenshenxiaonang recipe in the treatment of patients with Polycystic ovary syndrome (PCOS): a
multicenter, randomized, double-blind, placebo controlled trial
Methods Randomized parallel controlled trial







Trial name or title Letrozole, berberine, or their combination for anovulatory infertility in women with polycystic ovary syn-
drome: study design of a double-blind randomized controlled trial
Methods A multicentre randomized, double-blind trial
Participants Women with PCOS who desire pregnancy
Interventions 1. Letrozole and berberine.
2. Letrozole and berberine placebo.
3. Letrozole placebo and berberine.
Outcomes Live birth rate
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NCT01116167 (Continued)
Starting date October 2009
Contact information ClinicalTrials.gov identifier: NCT01116167
Notes
Abbreviations:PCOS: polycystic ovarian syndrome.
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D A T A A N D A N A L Y S E S
Comparison 1. CHM versus clomiphene




participants Statistical method Effect size
1 Pregnancy rate (per woman) 2 90 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [0.78, 5.06]
1.1 CHM versus clomiphene 1 60 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.44 [0.44, 4.73]
1.2 CHM + LOD versus
clomiphene + LOD
1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.35 [0.73, 15.36]
2 Ovulation rate (per woman) 1 30 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.42 [0.19, 10.49]
Comparison 2. CHM + clomiphene versus clomiphene




participants Statistical method Effect size
1 Pregnancy rate (per woman) 3 300 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.62 [1.65, 4.14]
1.1 CHM + clomiphene
versus clomiphene
2 130 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.45 [1.22, 4.95]
1.2 CHM + CEA +
clomiphene versus CEA +
clomiphene
1 170 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.75 [1.49, 5.04]
Comparison 3. CHM + follicle aspiration + ovulation induction versus follicle aspiration + ovulation induction




participants Statistical method Effect size
1 Pregnancy rate (per woman) 1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.60 [0.46, 5.52]
2 LUFS (adverse events) 1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.60 [0.06, 6.14]
3 OHSS (adverse events) 1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.16 [0.00, 8.19]
4 Multiple pregnancy (adverse
events)
1 44 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.60 [0.06, 6.14]
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Comparison 4. CHM + LOD versus LOD




participants Statistical method Effect size
1 Pregnancy rate (per woman) 1 30 Odds Ratio (Peto, Fixed, 95% CI) 3.5 [0.72, 17.09]
2 Ovulation rate (per woman) 1 30 Odds Ratio (Peto, Fixed, 95% CI) 2.43 [0.39, 15.08]
A D D I T I O N A L T A B L E S
Table 1. Contents of the formulations used in included studies
Study Type of intervention Formula
Liang 2008 Bushen Huoxue formula Basic formula: tu si zi 20 g, shu di 10 g, sang ji sheng 20 g, xian ling pi 15 g, bu gu zhi
10 g, huang jing 10 g, zao jiao ci 15 g, tao ren 10 g, shan ci gu 10 g, dan shen 10 g, gan
cao 6 g
plus huang qi 20 g, shan zha 10 g, fa ban xia 10 g in obese patients
plus zhi mu 10 g, huang qin 10 g in hirsutism or acne patients
Li 2007 CHM preparations Shenqi capsule: tu si zi 15 g, dang shen 20 g, ji xue teng 20 g, fu ling 15 g, dang gui 9
g, dan shen 15 g
Ling zhu infusion: yin yang huo 9 g, xian mao 9 g, dan nan xing 9 g, bai zhu 15 g, dang
gui 9 g, fa ban xia 9 g, fu ling 15 g
Ye 2007 CHM periodic therapy Basic formula: cang zhu 10 g, bai zhu 10 g, zhe bei mu 15 g, shi chang pu 15 g, dan
shen 10 g, xiang fu 10 g
1. Menstrual phase: basic formula plus tao ren 10 g, san qi 10 g, yi mu cao 15 g, for
3 to 5 days.
2. Late follicular phase: basic formula plus tu si zi 15 g, dang gui 9 g, shi di 10 g,
shan yu rou 10 g, fu ling 15 g, for 7 to 10 days.
3. Ovulation phase: basic formula plus lu lu tong 20 g, e zhu 10 g, bei qi 20 g, gui
zhi 9 g, for 3 days.
4. Luteinizing phase: basic formula plus tu si zi 15 g, dang gui 10 g, yin yang huo 10
g, rou gui 6 g, for 7 to 10 days.
Ma 2009a CHM formula Basic formula in ethinyloestradiol cyproterone acetate therapy phase
1. Yin deficiency of liver and kidney: shu di 30 g, dang gui 15 g, bai shao 15 g, shan
yu rou 15 g.
2. Deficiency of spleen and kidney: shu di 30 g, ba ji 30 g, fried bai zhu 30 g, ren
shen 15 g, raw huang qi 15 g, shan yu rou 9 g, gou qi zi 6 g, chai hu 1.5 g.
Periodic formula
1. Gui shao di huang soup at day 5 to 14 of menstrual cycle: dang gui 10 g, bai shao
15 g, shu di 15 g, shan yu rou 10 g, shan yao 10 g, fu ling 15 g, dan pi 10 g, ze xie 15 g.
2. Tao hong si wu soup at day 12 to 16 of menstrual cycle: shu di 10 g, dang gui 15
g, chi shao 15 g, chuan xiong 10 g, tao ren 10 g, hong hua 10 g.
3. Shou tao pellet after ovulation: tu si zi 20 g, sang ji sheng 15 g, e jiao 10 g, xu
duan.
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Table 1. Contents of the formulations used in included studies (Continued)
Li 2012a Compound Xuanju capsule Ingredients: hei ma yi , yin yang huo, gou qi zi, she chuang zi (patent medicine, detailed
prescription is not open)
Table 2. The name of CHM in different languages
Pingying name Latin name English name
Tu Si Zi Semen cuscutae dodder The seed of Chinese dodder
Shu Di Radix rehmanniae preparata Prepared rehmannia root
Sang Ji Sheng Parasitic loranthus Chinese taxillus twig
Xian Ling Pi Herba epimedii Herba epimedii
Bu Gu Zhi Fructus psoraleae Malaytea scurfpea fruit
Huang Jing Rhizoma polygonati Solomon’s seal
Zao Jiao Ci Spina gleditsiae Chinese honeylocust spine
Tao Ren Semen persicae Peach seed
Shan Ci Gu Pseudobulbus cremastrae seu pleiones Pseudobulb of appendiculate cremastra
Dan Shen Salvia miltiorrhiza The root of red-rooted salvia
Gan Cao Radix glycyrrhizae Licorice roots northwest origin
Huang Qi Stragalus membranaceus Membranous milk vetch root
Shan Zha Crataegus pinnatifida bge The fruit of a hawthorn
Fa Ban Xia Rhizoma pinellinae praeparata Pinellia tuber
Zhi Mu Rhizoma anemarrhenae Common anemarrhena rhizome
Huang Qin Scutellaria baicalensis Baical skullcap root
Dang Shen Codonopsis pilosula Root of hairy asiabell
Ji Xue Teng Lignum mililettiae Caulis spatholobi
Fu Ling Tuckahoe Poria cocos
Dang Gui Radix angelica Chinese angelica
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Table 2. The name of CHM in different languages (Continued)
Yin Yang Huo Herba epimedii Epimedium herb
Xian Mao Rhizoma curculiginis Common curculigo rhizome
Dan Nan Xing Bile arisaema Arisaema cum bile
Bai Zhu Atractylodes macrocephaia The rhizome of large headed atractylodes
Cang Zhu Rhizoma atractylodis The rhizome of Chinese atractylode
Zhe Bei Mu Fritillaria thunbergii Thunberbg fritillary bulb
Shi Chang Pu Rhizoma acori graminei Grassleaf sweelflag rhizome
Xiang Fu Rhizoma cyperi Nutgrass galingale rhizome
San Qi Pseudo-ginseng Panax notoginseng
Yi Mu Cao Leenurus heterophyllus Motherwort
Shan Yu Rou Fructus corni Common macrocarpium fruit
Lu Lu Tong Liquidambar formosana hance Beartiful sweetgum fruit
E Zhu Curcuma zedoary Zedoray rhizome
Bei Qi Radix astragali Northeast milkvetch root
Gui Zhi Ramulus cinnamomi Cassia twig
Rou Gui Cinnamomum cassia Chinese cinnamon
Bai Shao Radices paeoniae alba Root of herbaceous peony
Ba Ji Radix morindae officinalis Medicinal Indianmulberry root
Ren Shen Panax, gen-seng Ginseng
Shan Yao Rhizoma dioscoreae Common yam rhizome
Dan Pi Paeoniasuffruticosa The root bark of the peony tree
Ze Xie Rhizoma alismatic Oriental waterplantain rhizome
Chi Shao Radix paeoniae rubrathe Root of common peony
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Table 2. The name of CHM in different languages (Continued)
Chuan Xiong Ligusticum wallichii The rhizome of chuanxiong
Hong Hua Carthamus tinctorious Red flower
E Jiao Colla dorii asini Donkey hide gelatin
Xu Duan Radix dipsaci Teasel root
Hei Ma Yi Formicae populus infirmus quae nigra Black Ants
Yin Yang Huo Herba epimedii Epimedium Herb
Gou Qi Zi Fructus lycii Barbary Wolfberry Fruit
She Chuang Zi Fructus cnidii Common Cnidium Fruit
W H A T ’ S N E W
Last assessed as up-to-date: 9 June 2016.
Date Event Description
10 July 2016 New search has been performed The updated search found two ongoing studies (ChiCTR-
IOR-16008557; NCT01116167), and one new study (Li
2012a).
10 July 2016 New citation required but conclusions have not changed There is insufficient evidence for the conclusions of this
review to be changed
H I S T O R Y
Protocol first published: Issue 1, 2009
Review first published: Issue 9, 2010
Date Event Description
20 September 2010 Amended Contact details updated.
25 September 2008 Amended Title changed from ’Chinese herbal medicine for polycystic ovarian syndrome’ to ’Chinese herbal
medicine for subfertile women with polycystic ovary syndrome’; objectives were also changed
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(Continued)
22 September 2008 Amended Title changed from ’Chinese herbal medicine for the managment of polycystic ovarian syndrome’
to ’Chinese herbal medicine for polycystic ovarian syndrome’
C O N T R I B U T I O N S O F A U T H O R S
Kunyan Zhou updated the review, searched for trials, entered data entry into RevMan (RevMan 2014), extracted data, selected trials
for inclusion or exclusion, and contacted the primary study authors.
Jing Zhang drafted the protocol and original review; entered data into RevMan (RevMan 2014), and screened trials for inclusion or
exclusion.
Liangzhi Xu extracted data.
Taixiang Wu screened trials for inclusion or exclusion.
Danforn Lim revised and corrected the text.
D E C L A R A T I O N S O F I N T E R E S T
Kuanyan Zhou has no known conflicts of interest.
Jing Zhan has no known conflicts of interest.
Liangzhi Xu has no known conflicts of interest.
Taixiang Wu has no known conflicts of interest.
Chi Eung Danforn Lim has no known conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• West China Second University Hospital, Sichuan Universtiy, China.
• Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education,
China.
• Chinese Cochrane Center, West China Hospital, Sichuan University, China.
• National Natural Science Foundation of China (81270665), China.
• National Natural Science Foundation of China (41473097), China.
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External sources
• None, Other.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We searched more electronic databases in this review update than we listed in the original protocol ( Zhang 2009).
We added CHM+clomiphene versus clomiphene as a comparison in last review (Zhang 2010) that was not listed in the protocol (Zhang
2009). In this 2016 updated review we deleted this comparison as it was a duplicate.
N O T E S
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Clomiphene [therapeutic use]; Cyproterone Acetate [therapeutic use]; Drugs, Chinese Herbal [∗therapeutic use]; Ethinyl Estradiol
[therapeutic use]; Fertility Agents, Female [therapeutic use]; Infertility [∗drug therapy; etiology]; Laparoscopy; Ovulation Induction
[methods]; Polycystic Ovary Syndrome [complications; ∗therapy]; Pregnancy Rate; Randomized Controlled Trials as Topic; Suction
MeSH check words
Adult; Female; Humans; Pregnancy
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